The role of peroxisome proliferator-activated receptor ␣ (PPAR ␣ )-stimulated phospholipase A 2 (PLA 2 ) in cardiac mitochondrial cardiolipin (CL) biosynthesis was examined in both in vivo and in vitro models. Treatment of rat heart H9c2 cells with clofibrate increased the expression and activity of 14 kDa PLA 2 but did not affect the pool size of CL. Clofibrate treatment stimulated de novo CL biosynthesis via an increase in phosphatidylglycerolphosphate (PGP) synthase activity, accounting for the unaltered CL content. Cardiac PLA 2 , PGP synthase, and CDP-1,2-diacylsn -glycerol synthase (CDS-2) activities and CDS-2 mRNA levels were elevated in mice fed clofibrate for 14 days compared with controls. In PPAR ␣ -null mice, clofibrate feeding did not alter cardiac PLA 2 , PGP synthase activities, or CDS-2 activity and mRNA level, confirming that these enzymes are regulated by PPAR ␣ activation. In contrast to mouse heart, clofibrate treatment did not affect the activity or mRNA levels of CDS-2 in H9c2 cells, indicating that CDS-2 is regulated differently in rat heart H9c2 cells in vitro and in mouse heart in vivo. These results clearly indicate that cardiac CL de novo biosynthesis is stimulated by PPAR ␣ activation in responsive rodent models and that CDS-2 is an example of an enzyme that exhibits alternative regulation in vivo and in cultured cell lines. This study is the first to demonstrate that CL de novo biosynthesis is regulated by PPAR ␣
Phospholipids are important structural and functional components of the biological membrane (1). Structurally, as major components of the biological membrane, they define the compartmentalization of organelles and the protective barrier, the cell membrane, that surrounds cells. An important class of phospholipids are the polyglycerophospholipids. The major polyglycerophospholipid found in most mammalian tissues is bis-(1,2-diacyl-snglycero-3-phospho)-1 Ј ,3 Ј -sn -glycerol or cardiolipin (CL) (2) . CL was first isolated from beef heart in 1942 by Pangborn (3) . In rat liver, CL was initially shown to be associated exclusively with the inner mitochondrial membrane (4) . However, using various fractionation techniques, CL was identified also in the mitochondrial outer membrane of rat liver mitochondria (5) . In rat heart, CL is a major phospholipid component that constitutes ‫ف‬ 15% of the entire phospholipid phosphorus mass of the organ (6, 7) . CL is involved in modulation of the activity of a number of mitochondrial membrane enzymes involved in the generation of ATP (8) . It is well documented that alteration in the content and the molecular species composition of CL alters mitochondrial enzyme activity and oxygen consumption in mammalian mitochondria (9, 10) . Recently, CL has been implicated as an important mitochondrial factor that may be involved in the regulation of apoptosis (11, 12) . Thus, maintenance of the appropriate content of CL in cardiac mitochondria is essential for proper cardiac function.
The de novo biosynthesis of CL in the rat heart occurs via the CDP-1,2-diacyl-sn -glycerol (CDP-DG) pathway (2) . Phosphatidic acid (PA) is converted to CDP-DG by CDP-DG synthase (CDS; EC 2.2.7.41) (13) . In the rat heart and in embryonic rat heart-derived H9c2 myoblast cells, CDS may be a rate-limiting enzyme for CL biosynthesis (7, 14) .
The CDP-DG formed condenses with glycerol-3-phosphate to form phosphatidylglycerol (PG) catalyzed by PG phosphate (PGP) synthase (EC 2.7.8.5) and PGP phosphatase (EC 3.1.3.27) (13) . In the final step, PG is converted to CL by condensation with CDP-DG catalyzed by CL synthase (15) . CL may be hydrolyzed by mitochondrial phospholipase A 2 (PLA 2 ) (2) . Previously, we demonstrated that mitochondrial PLA 2 in rat embryonic H9c2 myoblastic cells could be activated by short-chain ceramides or tumor necrosis factor-␣ (TNF ␣ ) (16) . This activation of mitochondrial PLA 2 led to an increase in CL biosynthesis that was mediated by stimulation of mitochondrial PGP synthase activity.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily (17) (18) (19) . Three forms have been identified: PPAR ␣ , PPAR ␤ , and PPAR ␥ . It is well documented that the rat heart contains PPAR ␣ . Ethylp -chlorophenoxyisobutyrate (clofibrate) is a synthetic lipidlowering agent used in clinical practice. The effect of clofibrate on lipid metabolism in rodent heart is mediated by PPAR ␣ after heterodimering with the retinoid X receptor and interacting with PPAR response elements in the promotor regions of target genes. A recent study indicated that the mRNA of uncoupling protein-2 was elevated in neonatal cardiomyocytes and embryonic rat heart-derived H9c2 myoblast cells, probably through PPAR ␣ activation (20) . However, the presence of PPAR ␣ receptors in H9c2 cells was not examined in that study. Because PPAR ␣ activation stimulates PLA 2 activity (21, 22) , the role of this receptor in CL biosynthesis was examined in embryonic rat heart H9c2 myoblastic cells and mouse heart. The results show that activation of PPAR ␣ mediates increased CL biosynthesis and metabolism via an increase in mitochondrial PLA 2 and PGP synthase activities. However, activation of CDS-2, a rate-limiting enzyme of CL biosynthesis in rat heart embryonic H9c2 cells, is not necessary for the PPAR ␣ agonist-mediated stimulation of de novo CL biosynthesis. 
MATERIALS AND METHODS

Materials
Animals
Male C57BL/6N ϫ Sv/129 mice (25-35 g) were obtained from Central Animal Care Services (University of Manitoba, Winnipeg, Manitoba, Canada). PPAR ␣ -null ( Ϫ / Ϫ ) mice were a generous gift from Dr. Frank Gonzalez (National Institutes of Health). Treatment of mice conformed to the guidelines of the Canadian Council on Animal Care. The mice were maintained on rat chow and water ad libitum. All animals were kept in identical housing units on a cycle of 12 h of light and 12 h of darkness. In treatment groups, mice were fed 0.5% clofibrate in a chow diet for 14 days (23).
Culture, radiolabeling, and harvesting of H9c2 cells
Rat heart H9c2 myoblastic cells were grown and incubated in DMEM containing 10% FBS until 90% confluence was achieved. Cells were then incubated for 48 h with DMEM containing 10% FBS in the absence or presence of 200 M clofibrate or 5 M WY14,643. The medium was changed once after 24 h. In radiolabeling experiments, cells were then incubated with DMEM containing 10% FBS for up to 3 h with 0.1 M [1,3-3 H]glycerol (10 mCi/ml medium). The medium was removed and the cells were washed twice with ice-cold saline and then harvested from the dish with 2 ml of methanol-water (1:1, v/v) for lipid extraction. CL was separated from other phospholipids by two-dimensional TLC, and radioactivity incorporated into CL and other phospholipids was determined as described (14) . In some experiments, H9c2 cells were preincubated with 0.1 M [1-14 C]oleate (1.0 mCi/ml medium) for 24 h and then incubated in the absence or presence of 200 M clofibrate for up to 8 h, and the radioactivity incorporated into CL was determined.
Determination of in vitro enzyme activities
H9c2 cells were incubated for 48 h with DMEM containing 10% FBS in the absence or presence of 200 M clofibrate. The medium was changed once after 24 h. Subsequently, the cells were washed twice with ice-cold saline and harvested with 2 ml of homogenization buffer (10 mM Tris-HCL, pH 7.4, and 0.25 M sucrose). The cells were homogenized with 15 strokes of a Dounce A homogenizer. The homogenate (designated the cell lysate) was centrifuged at 1,000 g for 5 min, and the resulting supernatant was centrifuged at 10,000 g for 15 min. The pellet was resuspended in 0.5 ml of homogenization buffer and designated the mitochondrial fraction. CDS, PGP synthase, and CL synthase activities were determined as described (14) . In some experiments, 200 M clofibrate was added directly to the enzyme incubation mixture of mitochondrial fractions prepared from untreated H9c2 cells, and CDS, PGP synthase, and CL synthase activities were determined. PLA 2 activity was determined as described (24) . PA phosphohydrolase activity also was determined as described (25) .
Electrophoresis and Western blot analysis
H9c2 cells were incubated for 48 h with DMEM containing 10% FBS in the absence or presence of 50 M clofibrate. The medium was changed once after 24 h. The cells were harvested and homogenized, and mitochondrial fractions were prepared as described at PENN STATE UNIVERSITY, on February 23, 2013 www.jlr.org Downloaded from above. A 50 g aliquot of the homogenate or mitochondrial fraction was subjected to SDS-7.5% PAGE with molecular weight standards using a Bio-Rad (Hercules, CA) Mini-Protean ® II Dual Slab Cell electrophoresis unit. Proteins were transferred from the gel onto polyvinylidene difluoride (PVDF) membranes by incubation for 30 min at 15 V using a Bio-Rad Trans-Blot SD Semi-Dry Transfer Cell. Expression of PPAR ␣ was examined by incubating the PVDF membrane with the polyclonal anti-rat PPAR ␣ antibody (1:1,000 dilution) dissolved in Tris-buffered saline (TBS) containing 0.1% Tween 20 and 2% skim milk overnight at 4 Њ C. Subsequently, the membrane was washed and incubated with peroxidase-labeled anti-rabbit secondary antibody (1:5,000) for 5-30 min at room temperature. Protein bands in the membrane were visualized by enhanced chemiluminescence. For detection of 14 kDa PLA 2 , after transfer to PVDF membranes, the membranes containing protein samples were incubated with monoclonal anti-PLA 2 antibody (1:1,000). The membrane was then washed and incubated with the peroxidase-labeled anti-rabbit secondary antibodies (1:5,000) for 5-30 min at room temperature. The relative intensities of the bands were analyzed by scanning the film and subsequently determined using Scion Image software (22) .
Immunofluorescence confocal microscopy analysis
Sterilized glass coverslips were transferred to individual wells of 12-well culture plates. H9c2 cells were seeded on the plates (40,000 cells/well) for 24 h. Cells were then incubated for 48 h with DMEM containing 10% FBS in the absence or presence of 50 M clofibrate (40,000 cells/well). The medium was changed once after 24 h. The medium was then removed, and the cells were fixed with 3% paraformaldehyde for 15 min and then permeabilized using 3% paraformaldehyde and 0.3% Triton X-100 for 5 min at room temperature. The cells were next rinsed twice with buffer (10 mM MES, 150 mM NaCl, 5 mM EGTA, 5 mM MgCl 2 , and 5 mM glucose, pH 6.1), stored in sealed culture chambers with 1 ml of TBS buffer (20 mM Tris-HCl, 150 mM NaCl, 2.0 mM EGTA, and 2.0 mM MgCl 2 , pH 7.2), and stored. Cells could be stored for up to 2 weeks before analysis. The cells were then incubated with TBS containing 1% BSA and 2% sheep serum for 1 h. Coverslips were removed and inverted onto 20 l of the primary anti-cPLA 2 antibody and incubated overnight at 4 Њ C in a humidified chamber. The coverslip was then placed cell side up in 12-well culture dishes that were then immediately filled with 3 ml of TBS buffer containing 0.1% Tween 20. After 10 min, the buffer was removed and washed twice with TBS buffer containing 0.1% Tween 20. Coverslips were removed, inverted onto 20 l of the secondary antibody (diluted 1:100), and incubated in the dark for 2-3 h at room temperature in a humidified chamber. The coverslips were then washed three times as described above with TBS buffer containing 0.1% Tween 20. DNA of the cells was stained with propidium iodide (1 g/ml) in TBS buffer containing RNase (40 g/ml). After staining, coverslips were washed three times with double-distilled water and then twice with TBS buffer containing 0.1% Tween 20. Coverslips were then washed three times with double-distilled water and mounted cell side down onto glass slides prespotted with ProLong AntiFade mounting medium (Molecular Probes, Inc., Eugene, OR). Confocal image stacks, consisting of three to five sections obtained at 0.5 mm vertical intervals, were obtained using an Olympus (Tokyo, Japan) LX70 inverted microscope equipped with FluoView Laser Scanning hardware, including argon and krypton lasers to generate 488 and 568 nm lines for the detection of FITC and propidium iodide fluorescence, respectively.
RT-PCR analysis
The cDNA for CDS-2 was amplified with a pair of specific primers synthesized by Invitrogen™ Life Technologies (Carlsbad, CA). The rat CDS-2 primers used for the RT-PCR experiments were previously described (26): CDS-2 (U), 5 Ј -GAATCAGAG-TCGGAAGCA; and CDS-2 (L), 5 Ј -ACCAGGGCAAGTCGTAG. H9c2 cells were incubated for up to 72 h with 200 M clofibrate, and total RNA was isolated using the Trizol reagent according to the manufacturer's instructions. The RNA pellet was suspended in autoclaved, double-distilled water and quantitated by absorbance at 260 nm using the 260:280 nm ratio as an index of purity. The integrity of the RNA was confirmed by denaturing agarose gel electrophoresis of the isolated RNA sample. The firststrand cDNA from 1 g of total RNA was synthesized using 150 U of Moloney murine leukemia virus RT, 25 pmol of random hexamer primer, 20 U of RNase inhibitor, 1 mM dithiothreitol, and 10 pmol each of the four deoxynucleotides, in a total volume of 15 l. The reaction mixture was incubated at 37ЊC for 1 h and terminated by boiling the sample at 95ЊC for 5 min. An aliquot of the resulting cDNA preparation was used directly for each amplification reaction. PCR was performed in 20 l reaction mixtures containing 8 pmol of primer, 8 pmol of each deoxynucleotide trisphosphate, and 0.4 U of Taq DNA polymerase. The mixture was overlaid with 30 l of mineral oil to prevent evaporation and was incubated in a Perkin-Elmer (Foster City, CA) DNA Thermal Cycler under the following conditions. For the PCR of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) CDS-2: 25-30 cycles of denaturation for 1 min at 94ЊC, annealing for 1 min at 55-60ЊC, and extension for 2 min at 72ЊC. The amplified RT-PCR product was analyzed by 1.2-1.8% agarose gel electrophoresis in 1ϫ TAE buffer (40 mM Tris acetate and 2 mM sodium EDTA) and visualized by staining with 0.5 g/l ethidium bromide. The GAPDH band was used as an internal control. An increase in the level of a specific mRNA is caused by an increase in its rate of synthesis, a decrease in its rate of degradation, or a combination of these two processes. Hence, mRNA stability assays were conducted using actinomycin D as an inhibitor of RNA synthesis. H9c2 cells were incubated with 200 M clofibrate for 48 h, and 5 g/ml actinomycin D was added after clofibrate treatment. The mRNA levels for CDS-2 and GAPDH were determined by RT-PCR at 4 h intervals after the actinomycin treatment. No apparent changes in mRNA degradation were observed within a 24 h period, indicating that clofibrate did not cause any change in the degradation of CDS-2 mRNA.
Based on the primer pair used for rat CDS-2, a homologous primer pair for mouse, 5Ј-GAATCAGAGTCCGAAGCA and 5Ј-CTA-CGACCTGCCCTGGT (GenBank identifier gi31542373), was designed for RT-PCR of CDS-2 in mouse heart (GenBank identifier gi31542373). Primers for ␤-actin were 5Ј-GTGGGGCGCCCCAG-GCACCA-3Ј and 5Ј-CTCCTTAATGTCACGCACGATTTG-3Ј The conditions for amplification were 25 cycles of denaturation for 1 min at 94ЊC, annealing for 1 min at 55ЊC, and extension for 30 s at 72ЊC. The amplified RT-PCR product was analyzed as described above.
Other determinations
Protein was determined by the method of Lowry et al. (27) . Student's t-test was used to determine statistical significance. The level of significance was defined as P Ͻ 0.05.
RESULTS
Clofibrate stimulates the nuclear association of PPAR␣ in H9c2 cells
Acute activation of mitochondrial PLA 2 by TNF␣ or short-chain ceramide resulted in the stimulation of CL biosynthesis in rat heart H9c2 cardiac myoblast cells (16) .
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Previous studies indicated that PPAR␣ activation resulted in an increase in PLA 2 activity in human premonocytic cells and in rat mesangial cells (21, 22) . Because the heart contains PPAR␣, we examined whether activation of PLA 2 through a TNF␣-and ceramide-independent mechanism stimulated CL biosynthesis. Initially, we examined the nuclear expression of PPAR␣ in H9c2 cells with polyclonal anti-rat PPAR␣ antibody. H9c2 cells were grown to 90% confluence and harvested, and nuclear fractions were prepared. PPAR␣ receptor was expressed in the nuclear fraction of H9c2 cells (Fig. 1) .
PPAR␣ activation in rat Morris cells by ciprofibrate resulted in increased nuclear association of PPAR␣ (28) . We examined whether the addition to H9c2 cells of clofibrate, a known pharmacological activator of PPAR␣, resulted in increased nuclear association of PPAR␣. H9c2 cells were incubated for up to 4 h with 200 M clofibrate and then harvested, and nuclear fractions were prepared. We previously demonstrated that this concentration of clofibrate was shown to result in PPAR␣ activation in SW872 preadipocytes (22) . Incubation of H9c2 cells with clofibrate resulted in a rapid increase in nuclear PPAR␣ compared with untreated control cells (Fig. 1) . It is known that clofibrate may be toxic to tissue culture cells in high concentrations. We observed that 48 h of incubation of H9c2 cells with 200 M clofibrate did not affect the ability of these cells to exclude Trypan blue (98% exclusion). Thus, H9c2 cells contain PPAR␣, and clofibrate addition to H9c2 cells resulted in the activation of PPAR␣.
Activation of PPAR␣ in H9c2 cells stimulates mitochondrial PLA 2 activity
To determine whether the activation of PPAR␣ in H9c2 cells increased PLA 2 activity, cells were incubated in the absence or presence of 200 M clofibrate for 48 h and lysed, and PLA 2 activity was determined. As seen in Table  1 , treatment of H9c2 cells with clofibrate resulted in a 32% increase (P Ͻ 0.05) in membrane PLA 2 activity compared with control cells. We examined the mechanism for the increase in PLA 2 activity. We previously demonstrated that the expression of cytosolic PLA 2 activity and protein expression were upregulated by PPAR␣ in human premonocytic cells (22) (Fig. 2) . Thus, PPAR␣ activation by clofibrate resulted in an increase in the expression of cytosolic PLA 2 . However, because cytosolic PLA 2 does not have access to CL in mitochondria (29), we examined 14 kDa PLA 2 activity and protein expression in mitochondria. H9c2 cells were incubated for 48 h with 200 M clofibrate and lysed, mitochondrial fractions were prepared, PLA 2 activity was determined, and the presence of 14 kDa PLA 2 was examined by Western blot analysis. In- cubation of H9c2 cells with clofibrate resulted in a 34% increase (P Ͻ 0.05) in mitochondrial PLA 2 activity (Table  1 ) and a corresponding ‫%04ف‬ increase in 14 kDa PLA 2 protein associated with cell lysate membranes and mitochondrial membranes compared with controls (Fig. 3A,  B) . The 14 kDa PLA 2 protein was not observed in cytosolic fractions, indicating that there was no loss of the enzyme to the cytosol during subcellular fractionation (Fig. 3B) . Thus, PPAR␣ activation by clofibrate resulted in increases in mitochondrial 14 kDa PLA 2 enzyme activity and protein expression in H9c2 cells.
Activation of PPAR␣ in H9c2 cells stimulates CL biosynthesis
Because mitochondrial PLA 2 activity was elevated in H9c2 cells treated with clofibrate, we examined if the pool size of CL was reduced in these cells. The CL pool size was 7.5 Ϯ 0.2 nmol/mg cellular protein in H9c2 cells (average of three separate dishes) and was unaltered by clofibrate treatment (7.6 Ϯ 0.2 nmol/mg protein). We examined the metabolism of CL in cells incubated with clofibrate using a pulse-chase experimental approach. H9c2 cells were incubated for 24 h with [1-14 C]oleate, the medium was removed, the cells were incubated in the absence or presence of 200 M clofibrate for up to 8 h, and the radioactivity incorporated into CL was determined. Radioactivity incorporated into CL after 24 h of incubation with [1-14 C]oleate was 4.73 Ϯ 0.21 ϫ 10 4 dpm/mg protein (Fig. 4) . Radioactivity associated with CL was reduced during the chase in control cells but was reduced at a greater rate in cells treated with clofibrate. Thus, the presence of clofibrate resulted in an increase in CL turnover in H9c2 cells. Because the pool size of CL was unaltered yet mitochondrial PLA 2 and CL metabolism were increased by clofibrate treatment, it was possible that CL biosynthesis was increased in clofibrate-treated cells to maintain the CL pool size.
H9c2 cells were incubated with 200 M clofibrate or 5 M WY14,643 (a specific PPAR␣ agonist) for 48 h followed by incubation with 0.1 M [1,3-3 H]glycerol for 1 h, and radioactivity incorporated into phospholipids was determined. We previously demonstrated that this concentration of WY14,643 resulted in PPAR␣ activation in SW872 preadipocytes (22) . [1, H]Glycerol incorporation into CL was increased by 2-fold (P Ͻ 0.05) in clofibrate-treated cells and by 1.9-fold (P Ͻ 0.05) in WY14,643-treated cells compared with controls ( Table 2 ). In addition, [1, H]glycerol incorporation into PG, the immediate phospholipid precursor of CL, was increased by 34% (P Ͻ 0.05) in clofibrate-treated cells and by 30% (P Ͻ 0.05) in WY14,643-treated cells compared with controls. Total uptake of radioactivity into H9c2 cells was 3.11 ϫ 10 6 dpm/mg and was unaltered by clofibrate or WY14,643 treatment. Thus, the increase in glycerol incorporation into PG and CL in clofibrate-or WY14,643-treated cells was not attributable to an increase in the uptake of labeled glycerol into H9c2 cells.
The mechanism for the increase in the incorporation of [1, H]glycerol into CL was determined by assay of the enzymes of the CDP-DG pathway in mitochondrial fractions prepared from control and clofibrate-treated cells. H9c2 cells were incubated for 48 h with 200 M clofibrate, the cells were isolated and homogenized, and mitochondrial fractions were prepared. CDS, PGP synthase, and CL synthase activities were determined in these mitochondrial fractions. Treatment of cells with clofibrate resulted in a 37% increase (P Ͻ 0.05) in the activity of PGP synthase ( Table 3) . In contrast, CDS and CL synthase activities were unaltered compared with those of controls. As previously shown (25) , 20% of total PA phosphohydrolase activity was localized to membranes of H9c2 cells, and treatment with clofibrate did not alter the amount of activity associated with membranes (data not shown). Finally, the addition of clofibrate to the incubation mixture of mitochondrial fractions prepared from untreated H9c2 cells was examined. CDS, PGP synthase, and CL synthase activities were 2.5 Ϯ 0.4, 498 Ϯ 47, and 3.0 Ϯ 0.5 pmol/ min/mg protein, respectively, and were unaltered by the presence of 200 M clofibrate in the incubation mixture.
Activation of PPAR␣ in mice stimulates CL biosynthesis and metabolism
To confirm the PPAR␣ agonist-mediated stimulation of cardiac CL biosynthesis, cardiac CL metabolism was examined in another PPAR␣-responsive rodent model. Mice were fed 0.5% clofibrate for 14 days, the hearts were removed, and the activities of the mitochondrial CL biosynthetic enzymes and PLA 2 activity were determined. As seen in Table 4 , clofibrate treatment of mice resulted in a 36% (P Ͻ 0.05) and a 75% (P Ͻ 0.05) increase in cardiac PLA 2 and PGP synthase activities, respectively, compared with those of untreated mice. CL synthase activity was unaltered by clofibrate treatment. In contrast to H9c2 cells, CDS activity was increased by 3-fold (P Ͻ 0.05) in clofibrate-treated mice compared with untreated mice. These data appeared to indicate that CDS activity is regulated differently by clofibrate in these two different PPAR␣-responsive rodent models. To further confirm this and to confirm that PLA 2 and PGP synthase activities are indeed regulated by PPAR␣ activation, the activities of these enzymes were examined in PPAR␣-null mice treated with clofibrate. PLA 2 , CDS, PGP synthase, and CL synthase activities were unaltered in clofibrate-treated PPAR␣-null mice compared with controls. Thus, cardiac mitochondrial PLA 2 , PGP synthase, and CDS activities are regulated by PPAR␣ activation in mouse heart. CDS-1 mRNA is not expressed in mammalian heart (30). Thus, we examined the expression of CDS-2 in H9c2 cells treated with clofibrate. The validity of RT-PCR quantitation for both rat and mouse CDS-2 is provided in Fig.  5 . As seen in Fig. 6 , the expression of CDS-2 mRNA in 
Mice were fed 0.5% clofibrate for 14 days, cardiac mitochondrial fractions were prepared, and mitochondrial CDS, PGP synthase, CL synthase, and PLA 2 activities were determined. Values represent means Ϯ SD of three animals.
a P Ͻ 0.05. H9c2 cells was unaltered by incubation with clofibrate for up to 72 h. Thus, CDS-2 is not upregulated during PPAR␣ activation in H9c2 cells. We then examined CDS-2 mRNA expression in hearts of wild-type and PPAR␣-null mice. As seen in Fig. 7 , the expression of cardiac CDS-2 mRNA was increased by 59% in wild-type but not in PPAR␣-null mice treated with clofibrate. We conclude that CL de novo biosynthesis is regulated by PPAR␣ activation in both mouse heart and rat heart embryonic H9c2 cells. However, because CDS activity and mRNA expression were unresponsive to PPAR␣ agonist activation in rat heart H9c2 cells but cardiac CDS activity and mRNA expression were increased in mice treated with clofibrate, we hypothesize that this enzyme may be differentially regulated in different PPAR␣-responsive rodent models.
DISCUSSION
The objective of this study was to examine whether CL biosynthesis was regulated by PPAR␣. The results indicate the following: 1) rat heart myoblastic H9c2 cells contain PPAR␣; 2) clofibrate treatment of H9c2 cells stimulates the nuclear association of PPAR␣; 3) clofibrate stimulation of PPAR␣ in H9c2 cells results in an increase in mitochondrial PLA 2 and CL de novo biosynthesis; 4) the mechanism for the increase in CL biosynthesis in H9c2 cells is an increase in PGP synthase activities; and 5) CDS-2 is a PPAR␣ agonist-responsive gene in mouse heart but not in rat heart H9c2 cells.
The fibrates, including clofibrate, fenofibrate, and gemfibrozil, are a class of drugs that effectively lower plasma levels of VLDLs and triacylglycerides in humans, primates, and rodent species (17) (18) (19) (31) (32) (33) . These drugs mediate their effect by binding to PPAR␣ and enhancing the expression of specific target genes. Western blot analysis revealed the presence of PPAR␣ receptors in rat heart myoblastic H9c2 cells.
Incubation of human premonocytic SW872 preadipocytes and rat mesangial cells with clofibrate results in the activation of cPLA 2 and sPLA 2 enzyme activities, respectively (21, 22) . Treatment of H9c2 cells with clofibrate resulted in an increase of both cPLA 2 and the expression and activity of 14 kDa PLA 2 -IIA in mitochondrial fractions. However, the pool size of CL remained unaltered. We previously demonstrated that activation of mitochondrial PLA 2 by TNF␣ or N-acetylsphingosine produced a compensatory increase in de novo CL biosynthesis via the activation of PGP synthase activity to maintain the intracellular CL pool (16) . Thus, 14 kDa PLA 2 -IIA is identified as a potential PPAR␣ target gene in H9c2 cells.
Incubation of H9c2 cells with clofibrate resulted in an increase in [1, H]glycerol incorporation into CL and its immediate phospholipid precursor, PG. Some lipid-lowering or hypolipidemic drugs are known to inhibit PA phosphohydrolase activity, causing a redirection of lipid synthesis away from DG production toward CDP-DG-utilizing reactions (e.g., PG and phosphatidylinositol). Thus, incubation of cells with these compounds could erroneously affect [1, H]glycerol incorporation into various phospholipids. Clofibrate had little effect on the synthesis of glycerides, phospholipids, phosphatidate phosphohydrolase, or DG acyltransferase activities in rat liver slices (34) . In agreement with these observations, PA phosphohydrolase activity in rat myoblastic H9c2 cells was unaltered by clofibrate preincubation. Thus, the observed increase in [1, H]glycerol incorporation into PG and CL was attributable to a direct effect on the enzymes of the CL biosynthetic pathway.
Incubation of rat heart H9c2 cells with clofibrate resulted in an increase in PGP synthase activity that would explain the increase in CL biosynthesis from [1, H]glyc- Fig. 7 . Effect of clofibrate on CDS-2 mRNA levels in wild-type and PPAR␣-null mice. Wild-type and four PPAR␣-null mice were fed either a control or a clofibrate diet for 14 days (two animals from each group). The hearts were removed, and mRNA levels were determined by RT-PCR as described in Materials and Methods. The blots represent the two animals from each group. The relative intensities of the bands were analyzed using Scion Image software. erol in these cells. CDS may be a rate-limiting enzyme of CL biosynthesis in the rat heart and in rat embryonic heart H9c2 cells (7, 14) . There are two known isoforms of the enzyme, CDS-1 and CDS-2, and CDS-1 is not expressed in mammalian heart (30) . Surprisingly, treatment of H9c2 cells with clofibrate did not affect CDS enzyme activity. In addition, clofibrate administration directly to H9c2 cell mitochondrial fractions did not affect CDS activity (data not shown). Finally, clofibrate treatment did not affect CDS-2 mRNA levels in H9c2 cells. These data clearly indicate that CDS-2 is not a PPAR␣ target gene in rat heart H9c2 cells. In contrast to rat H9c2 cells, CDS activity was increased by 3-fold in cardiac mitochondrial fractions prepared from mice treated with clofibrate but was unaltered when PPAR␣-null mice were treated with clofibrate. In addition, CDS mRNA level was increased by 59% in hearts from mice treated with clofibrate but was unaltered when PPAR␣-null mice were treated with clofibrate. These data clearly indicate that CDS is a PPAR␣ agonist-responsive gene in mouse heart but not in rat heart H9c2 cells. Finally, clofibrate treatment stimulated cardiac mitochondrial PLA 2 and PGP synthase activities in mouse. These enzyme activities were unaltered in PPAR␣-null mice treated with clofibrate, indicating that they are responsive to PPAR␣ agonist stimulation. Taken together, using two different rodent models, the data clearly indicate that de novo CL biosynthesis is regulated by PPAR␣. It is still not certain whether these effects are directly or indirectly regulated by PPAR␣.
What is the implication of increased mitochondrial CL biosynthesis during clofibrate treatment of rat H9c2 cells and mouse heart? Mice and rats are particularly responsive to the biological effects of fibrates (31, 32) . In contrast, there is currently no direct evidence to indicate that guinea pigs and humans are responsive to the proliferative effects of these drugs. Mitochondria appear to be one of the principal intracellular targets for nutritional and pharmacological control of lipid metabolism mediated by the fibrates (35) . Fenofibrate feeding increased rat liver mitochondrial ␤-oxidation, and this was associated with a decrease in triacylglyceride synthesis and secretion. In the rat heart, increased CL biosynthesis and remodeling were associated with increased mitochondrial ␤-oxidation (36) (37) (38) . Thus, the clofibrate-induced increase in CL biosynthesis and metabolism in H9c2 cells and mouse heart may be linked to increased mitochondrial metabolism required for cellular proliferation in these rodents. Alternatively, the increase in CL biosynthesis may be a compensatory mechanism by the cell to maintain the CL pool when CL is degraded by phospholipases. We previously demonstrated that the addition of the proapoptotic factor TNF␣ to H9c2 cells resulted in the activation of mitochondrial PLA 2 activity and increased CL degradation, which in turn resulted in the activation of PGP synthase and increased CL biosynthesis from [1, H]glycerol (16) . Given the importance of CL loss (11, 12) and the accumulation of its immediate metabolic product, monolysocardiolipin (39) , in mitochondrion-mediated apoptosis, it is possible that rapid CL synthesis is required in response to proapoptotic stimuli-mediated CL degradation to restore cellular homeostasis and prevent a cell's entrance into apoptosis. Hence, increased CL biosynthesis may be a protective mechanism against apoptosis.
In summary, rat heart myoblastic H9c2 cells contain PPAR␣, and its activation results in an increase in de novo CL biosynthesis. In addition, PGP synthase and PLA 2 were identified as possible PPAR␣ agonist-responsive enzymes involved in the regulation of CL biosynthesis in the mouse heart. Furthermore, CDS-2 was identified as a PPAR␣ agonist-responsive gene and appears to be differentially regulated by PPAR␣ activation between rat cardiac H9c2 cells and mouse heart models.
